24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Hot Flashes

Interventions

DRUG: Brisdelle (paroxetine mesylate)
DRUG: Placebo capsules

Sponsor

Noven Therapeutics